Celgene is reportedly in talks to buy a $5.5 billion cancer drugmaker
Business Insider -

Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday.

If the deal materializes, it'd be the second in 2018 for the biotech giant, which has been under pressure from investors.

Juno is known for its experimental treatments that harness the body's immune system to treat cancer. 

Biotech giant Celgene is in talks to buy cancer drugmaker Juno Therapeutics, The Wall Street Journal reports. 

Celgene has been under pressure from investors to make some changes...

Loading...

Related Articles